Palisade Bio (NASDAQ:PALI) Director Purchases $39,600.00 in Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera bought 20,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was bought at an average cost of $1.98 per share, with a total value of $39,600.00. Following the completion of the transaction, the director owned 356,904 shares in the company, valued at approximately $706,669.92. This trade represents a 5.94% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Robert Jr. Baltera also recently made the following trade(s):

• On Tuesday, July 7th, Robert Jr. Baltera purchased 30,000 shares of Palisade Bio stock. The shares were bought at an average price of $2.03 per share, for a total transaction of $60,900.00.
• On Monday, July 6th, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was bought at an average cost of $2.05 per share, with a total value of $41,000.00.
• On Thursday, July 2nd, Robert Jr. Baltera purchased 10,000 shares of Palisade Bio stock. The stock was bought at an average cost of $1.98 per share, with a total value of $19,800.00.

Palisade Bio Price Performance

Shares of PALI opened at $2.05 on Thursday. The company has a 50-day simple moving average of $1.92 and a two-hundred day simple moving average of $1.92. The firm has a market capitalization of $355.84 million, a PE ratio of -2.03 and a beta of 1.50. Palisade Bio, Inc. has a one year low of $0.53 and a one year high of $2.86.

Palisade Bio (NASDAQ:PALI) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Analysts expect that Palisade Bio, Inc. will post -0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Palisade Bio

Several large investors have recently modified their holdings of PALI. Perceptive Advisors LLC bought a new position in Palisade Bio in the 4th quarter worth about $28,318,000. Commodore Capital LP purchased a new position in Palisade Bio in the fourth quarter worth about $26,896,000. Janus Henderson Group PLC purchased a new position in Palisade Bio in the fourth quarter worth about $24,822,000. RA Capital Management L.P. bought a new position in shares of Palisade Bio in the fourth quarter worth approximately $16,742,000. Finally, Eversept Partners LP purchased a new stake in shares of Palisade Bio during the fourth quarter valued at approximately $12,670,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Palisade Bio News Roundup

Here are the key news stories impacting Palisade Bio this week:

• Positive Sentiment: Director Robert Jr. Baltera bought 30,000 shares at about $2.03 per share, following earlier purchases of 20,000 shares and 10,000 shares at $1.98. Repeated insider buying can signal confidence in Palisade Bio’s outlook. SEC filing
• Positive Sentiment: Analysts remain broadly constructive on Palisade Bio, with recent ratings including a “strong-buy” upgrade and multiple buy ratings, plus a consensus price target well above the current trading range. MarketBeat PALI page
• Neutral Sentiment: CEO John David Finley sold 146,798 shares, but the filing says the transaction was to cover tax withholding obligations tied to vesting equity awards, which makes the sale less concerning than a discretionary insider exit. SEC filing
• Neutral Sentiment: Insider Mitchell Lawrence Jones also sold shares for the same tax-withholding reason, adding to the day’s mixed insider activity. SEC filing

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PALI. Weiss Ratings raised shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. Oppenheimer set a $7.00 price objective on shares of Palisade Bio in a research note on Tuesday, June 30th. Wolfe Research initiated coverage on shares of Palisade Bio in a report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price objective on the stock. LADENBURG THALM/SH SH raised shares of Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Finally, Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a report on Sunday. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Palisade Bio has a consensus rating of “Buy” and a consensus price target of $8.83.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.